Beam Therapeutics to Present Initial BEAM-301 Trial Data
The company says initial Phase 1/2 data show restoration of endogenous glucose production after a single treatment, with dose-dependent improvements in key GSDIa endpoints.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Beam Therapeutics reports initial Phase 1/2 data for BEAM — 301 in glycogen storage disease type Ia trial
Beam Therapeutics flagged initial Phase 1/2 results for BEAM-301 in glycogen storage disease type Ia for presentation at ESGCT. Data showed signs of restored patients’ ability to maintain glucose levels following a single dose, with stronger effects at higher dosing. Patients reduced reliance on frequent starch dosing,
Beam Therapeutics to Present BEAM-301 Phase 1/2 Data at ESGCT Congress
The company said it will present initial data from its BEAM-301 Phase 1/2 trial in glycogen storage disease type Ia at the ESGCT 33rd Annual Congress.